Figure 7.
Development of antihistone IgG in temporal relationship to mRNA vaccination. (A) Antihistone IgG titers in 2 of 144 vaccinated participants of the SeCo study, who received 2 shots of mRNA-based COVID-19 vaccines. (B) Platelet activation analysis with the sera of vaccinees who tested positive for antihistone IgG. Platelets of healthy donors were washed and incubated with the vaccinees’ sera. Each dot represents the mean of at least 3 tests. No procoagulant platelet formation was detected by testing PS exposure after annexin-V staining in flow cytometry. Negative control: phosphate buffered saline; positive control: 20 μM thrombin receptor activating peptide + 100 ng/mL convulxin. PBS, phosphate-buffered saline; TRAP/Conv, thrombin receptor activating peptide + convulxin; vacc., vaccination.

Development of antihistone IgG in temporal relationship to mRNA vaccination. (A) Antihistone IgG titers in 2 of 144 vaccinated participants of the SeCo study, who received 2 shots of mRNA-based COVID-19 vaccines. (B) Platelet activation analysis with the sera of vaccinees who tested positive for antihistone IgG. Platelets of healthy donors were washed and incubated with the vaccinees’ sera. Each dot represents the mean of at least 3 tests. No procoagulant platelet formation was detected by testing PS exposure after annexin-V staining in flow cytometry. Negative control: phosphate buffered saline; positive control: 20 μM thrombin receptor activating peptide + 100 ng/mL convulxin. PBS, phosphate-buffered saline; TRAP/Conv, thrombin receptor activating peptide + convulxin; vacc., vaccination.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal